Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the past year to ($1.08), which beat the estimate of ($1.09).

Recap: Revance Therapeutics Q1 Earnings

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update

Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021

Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q1 Earnings Expected to Decline

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Share Data at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA's 24-Week Duration Profile Across Multiple Female Age Cohorts

Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA's 24-Week Long Duration Profile Across Multiple Female Age Cohorts

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference

Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at AAN Annual 2021 Meeting

Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?

Allergan

Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is projected to grow at a CAGR of 14.22% to reach US$21.727 billion by 2025 from US$9.780 billion in 2019. Products pertaining to facial injectables which are also referred to as dermal fillers that are intended to reconstruct, bioengineer facial features as well for facial rejuvenation to rectify wrinkles caused due to the loss of subcutaneous fat over the face that is experienced by individuals as they grow old. The products are necessary for treating early signs of aging or complement facial rejuvenation surgery. Additionally, the growing consciousness about appearance along with the increasing pool of geriatric population is the primary driver that is estimated to catapult the facial injectable market to new heights during the forecast period. Moreover, the increasing shift towards minimally invasive procedures and continuous developers in glacial rejuvenation is expected to further augment the growth for the same market. Additionally, the rising awareness regarding the accessibility of various products and procedures, which has stemmed due to the increasing number of players entering the facial injectables space across the globe is forecasted to further add to the surge that the market is expected to witness. Besides, the importance of skincare has gained quite a momentum as exemplified by the fact that 71,800 jobs in 2018 were held by skincare specialists, 47% of which were employed by personal care services in the United States. Additionally, the projected employment in 2028 is estimated at 79,600 [Source: U.S. Bureau of Labor Statistics]. Further, individualistic value-driven rational has superseded the generic mob mentality of the yesteryears which incentivizes today's consumers to look for products that more oriented to themselves. Further, this interest has also fueled investments in various research studies like that of DREAM (Dysport Real-world Evaluation and Measured satisfaction study) carried out by Galderma after which in May 2020, it announced 95% of patients treated with Dysport achieved high levels of satisfaction with two treatments per year, and 97% of patients believed the result of the treatment looked natural. Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. In the same year, HUONS announced that the Korean Ministry of Food and Drug Safety has given it the approval to conduct phase 2 clinical trials for Liztox, its independently developed botulinum toxin (BTX) product that has launched in June 2019, for treating square jaws. Moreover, form the perspective of increasing market reach, in 2020 Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering innovations in neuromodulators for aesthetic and therapeutic indications, announced the signing of a U.S. distribution agreement with TEOXANE SA. Under this agreement, Revance is the exclusive commercialization partner of the Swiss company's modern and innovative Resilient Hyaluronic Acid (RHA) technology. TEOXANE's RHA line of fillers include U.S. Food and Drug Administration (FDA)-approved RHA 2, RHA 3, and RHA 4 products, which include lidocaine. The RHA line was designed using a patented crosslinking method that preserves the hyaluronic acid network for correction of moderate-to-severe dynamic facial wrinkles and folds optimizing strength, stretch, and tissue integration. It provides physicians with a broad range of uniquely designed gels for individualized treatment in the face. Further due to the upward trend there has been a new development in the aesthetics armlet particularly that pertaining to the facial Injectable market. For instance, in 2020, despite the COVID 19, Galderma announced that "Restylane Kysse" - it's lip filler lip augmentation product, received FDA. Again, Revance Therapeutics, Inc recently announced that the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI), which is its next generation neuro modular product aimed at treating moderate to severe glabellar (frown) lines, has been accepted for review by the U.S. Food and Drug Administration (FDA). In 2019 The HydraFacialT Company announced that it has entered into a partnership with Advanced Dermatology and Cosmetic Surgery, the largest dermatology practice in the United States. Furthermore, Allergan plc (NYSE: AGN) announced that it received U.S. Food and Drug Administration (FDA) approval for the use of Juvederm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDET cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21 years. In 2018, Restylane Lyft with Lidocaine, by Q-Med AB was approved by FDA for implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds, subcutaneous to subperiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21. Thus, from the aforesaid, it is evident that the facial injectable market is expected to witness a significant rise during the forecast period, nevertheless, certain adverse effects Viz. allergic reactions, nausea, skin rash, as well as neck and back pain, are expected to deter the growth. Further regularity issues pertaining to botulinum toxin type A, is also expected to pose a hindrance to market growth during the forthcoming years. Key Topics Covered: 1. Introduction 1.1. Market Definition1.2. Market Segmentation 2. Research Methodology 2.1. Research Data2.2. Assumptions 3. Executive Summary 3.1. Research Highlights 4. Market Dynamics 4.1. Market Drivers4.2. Market Restraints4.3. Porters Five Forces Analysis4.3.1. Bargaining Power of Suppliers4.3.2. Bargaining Power of Buyers4.3.3. The threat of New Entrants4.3.4. Threat of Substitutes4.3.5. Competitive Rivalry in the Industry4.4. Industry Value Chain Analysis 5. Facial Injectable Market Analysis, By Type 5.1. Introduction5.2. Botulinum Toxin5.3. Collagen5.4. Hyaluronic Acid5.5. Particle & Polymer Fillers (PPF)5.5.1. Calcium Hydroxyapatite5.5.2. Poly-l-Lactic Acid5.5.3. Polymethylmethacrylate 6. Facial Injectable Market Analysis, By Generation 6.1. Introduction6.2. Gen X6.3. Boomer6.4. Millennials 7. Facial Injectable Market Analysis, By End-User 7.1. Introduction7.2. Dermatology & Beauty Clinics7.3. Hospitals7.4. Research Institutes 8. Facial Injectable Market Analysis, by Geography 8.1. Introduction8.2. North America8.2.1. North America Facial Injectable Market Analysis, By Product Type8.2.2. North America Facial Injectable Market Analysis, By Generation8.2.3. North America Facial Injectable Market Analysis, By End-Users8.2.4. By Country8.2.4.1. USA8.2.4.2. Canada8.2.4.3. Mexico8.3. South America8.3.1. South America Facial Injectable Market Analysis, By Product Type8.3.2. South America Facial Injectable Market Analysis, By Generation8.3.3. South America Facial Injectable Market Analysis, By End-Users 8.3.4. By Country8.3.4.1. Brazil8.3.4.2. Argentina8.3.4.3. Others8.4. Europe8.4.1. Europe Facial Injectable Market Analysis, By Product Type8.4.2. Europe Facial Injectable Market Analysis, By Generation8.4.3. Europe Facial Injectable Market Analysis, By End-Users8.4.4. By Country8.4.4.1. Germany8.4.4.2. France8.4.4.3. United Kingdom8.4.4.4. Italy8.4.4.5 Others8.5. The Middle East and Africa8.5.1. Middle East and Africa Facial Injectable Market Analysis, By Product Type8.5.2. Middle East and Africa Facial Injectable Market Analysis, By Generation8.5.3. Middle East and Africa Facial Injectable Market Analysis, By End-Users8.5.4. By Country8.5.4.1. Israel8.5.4.2. Saudi Arabia8.5.4.3. Others8.6. Asia Pacific8.6.1. Asia Pacific Facial Injectable Market Analysis, By Product Type8.6.2. Asia Pacific Facial Injectable Market Analysis, By Generation8.6.3. Asia Pacific Facial Injectable Market Analysis, By End-Users8.6.4. By Country8.6.4.1. China8.6.4.2. Japan8.6.4.3. South Korea8.6.4.4. India8.6.4.5. Others 9. Competitive Environment and Analysis 9.1. Major Players and Strategy Analysis9.2. Emerging Players and Market Lucrativeness9.3. Mergers, Acquisitions, Agreements, and Collaborations9.4. Vendor Competitiveness Matrix 10. Company Profiles 10.1. Allergan (AbbVie Inc)10.2. Bausch Health Companies Inc.10.3. Bloomage Biotechnology Corporation Limited10.4. Galderma 10.5. Johnson Medical Aesthetics, LLC10.6. Merz Pharma10.7. Prollenium Medical Technologies10.8. Sanofi 10.9. Sinclair Pharma10.10. Suneva Medical For more information about this report visit https://www.researchandmarkets.com/r/4fn9up

Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography

PolarityTE Inc

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Revance Therapeutics Inc (NASDAQ: RVNC) has reported topline data from JUNIPER Phase 2 study evaluating DaxibotulinumtoxinA for Injection to treat adults with moderate to severe upper limb spasticity. It is a neurological condition that affects the ability to move the arms and affects hands, fingers, wrist, forearm, elbow, and shoulder.

Revance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb Spasticity

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2020 Results - Earnings Call Transcript

Shares of Revance Therapeutics (NASDAQ:RVNC) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 25.25% year over year to ($1.24), which were in line with the estimate of ($1.24).

Recap: Revance Therapeutics Q4 Earnings

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2020 Financial Results

Revance Reports Fourth Quarter and Full Year 2020 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of ULS

Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Olivia C. Ware and Carey O'Connor Kolaja to Board of Directors

Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O'Connor Kolaja, to its Board of Directors

On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance Therapeutics is included in the following report.

Revance Therapeutics's Earnings Outlook

NASHVILLE, Tenn.--(BUSINESS WIRE)--Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville

Governor Lee, Commissioner Rolfe Announce Revance Therapeutics to Relocate Global Headquarters to Nashville

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.

Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript

Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year to ($1.34), which missed the estimate of ($1.03).

Recap: Revance Therapeutics Q3 Earnings

Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Revance (RVNC) This Earnings Season?

Revance Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rating appeared first on Investor's Business Daily.

Stocks Showing Market Leadership: Revance Therapeutics Earns 93 RS Rating

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2020 Results - Earnings Call Transcript

News for Revance Therapeutics Stock (RVNC)